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Abstract
 
After erythropoietin (rHuEPO) therapy, patients with
chronic renal failure (CRF) do not improve peak O
 
2
 
 uptake
( O
 
2
 
 peak) as much as expected from the rise in hemoglobin
concentration ([Hb]). In a companion study, we explain this
phenomenon by the concurrent effects of fall in muscle
blood flow after rHuEPO and abnormal capillary O
 
2
 
 con-
ductance observed in CRF patients. The latter is likely asso-
ciated with a poor muscle microcirculatory network and
capillary-myofiber dissociation due to uremic myopathy.
Herein, cellular bioenergetics and its relationships with
muscle O
 
2
 
 transport, before and after rHuEPO therapy,
were examined in eight CRF patients (27
 
6
 
7.3 [SD] yr)
studied pre- and post-rHuEPO ([Hb] 
 
5
 
 7.8
 
6
 
0.7 vs.
11.7
 
6
 
0.7 g 
 
3
 
 dl
 
2
 
1
 
) during an incremental cycling exercise
protocol. Eight healthy sedentary subjects (26
 
6
 
3.1 yr)
served as controls. We hypothesize that uremic myopathy
provokes a cytosolic dysfunction but mitochondrial oxida-
tive capacity is not abnormal. 
 
31
 
P-nuclear magnetic reso-
nance spectra (
 
31
 
P-MRS) from the vastus medialis were ob-
tained throughout the exercise protocol consisting of
periods of 2 min exercise (at 1.67 Hz) at increasing work-
loads interspersed by resting periods of 2.5 min. On a different
day, after an identical exercise protocol, arterial and femo-
ral venous blood gas data were obtained together with simul-
taneous measurements of femoral venous blood flow ( leg)
to calculate O
 
2
 
 delivery ( O
 
2
 
leg) and O
 
2
 
 uptake ( O
 
2
 
leg).
Baseline resting [phosphocreatine] to [inorganic phosphate]
ratio ([PCr]/[Pi]) did not change after rHuEPO (8.9
 
6
 
l.2 vs.
8.8
 
6
 
1.2, respectively), but it was significantly lower than in
controls (10.9
 
6
 
1.5) (
 
P
 
 
 
5
 
 0.01 each). At a given submaximal
or peak O
 
2
 
leg, no effects of rHuEPO were seen on cellular
bioenergetics ([PCr]/[Pi] ratio, %[PCr] consumption, half-
time of [PCr] recovery after exercise), nor in intracellular
pH (pHi). The post-rHuEPO bioenergetic status and pHi, at
a given O
 
2
 
leg, were below those observed in the control
group. However, at a given pHi, no differences in 
 
31
 
P-MRS
data were detected between post-rHuEPO and controls. Af-
ter rHuEPO, at peak O
 
2
 
, leg fell 20% (
 
P
 
 
 
,
 
 0.04), limiting
V
.
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V
.
V
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the change in O
 
2
 
leg to 
 
1
 
17%, a value that did not reach
statistical significance. The corresponding O
 
2
 
 extraction ra-
tio decreased from 73
 
6
 
4% to 68
 
6
 
8.2% (
 
P
 
 
 
,
 
 0.03). These
changes indicate that maximal O
 
2
 
 flow from microcircula-
tion to mitochondria did not increase despite the 50% in-
crease in [Hb] and explain how peak O
 
2
 
leg and cellular
bioenergetics (
 
31
 
P-MRS) did not change after rHuEPO. Dif-
ferences in pHi, possibly due to lactate differences, between
post-rHuEPO and controls appear to be a key factor in the
abnormal muscle cell bioenergetics during exercise observed
in CRF patients. (
 
J. Clin. Invest.
 
 1996. 97:2101–2110.) Key
words: energy metabolism 
 
•
 
 exercise 
 
•
 
 muscle O
 
2
 
 transport 
 
•
 
oxygen transport 
 
•
 
 O
 
2
 
max
 
Introduction
 
It is known that substantial increases in hemoglobin concentra-
tion ([Hb])
 
1
 
 after erythropoietin (rHuEPO) therapy in pa-
tients with chronic renal failure (CRF) are not followed by cor-
responding gains of maximum O
 
2
 
 uptake ( O
 
2
 
max) (1–9). In
a previous study with CRF patients (10), O
 
2
 
 supply depen-
dency of O
 
2
 
max was demonstrated. This indicates that peak
O
 
2
 
 is not determined by mitochondrial oxidative limits. The
dissociation between increase in [Hb] and the changes of
O
 
2
 
max after rHuEPO was explained by two factors affecting
O
 
2
 
 transport to the cell.
First, correction of anemia with rHuEPO therapy results in
elimination of the hyperdynamic cardiac status. This returns
elevated muscle blood flow ( ) to values similar to levels seen
in matched control subjects during peak exercise and partially
offsets the effect of the rise in arterial O
 
2
 
 content on O
 
2
 
 deliv-
ery. Second, O
 
2
 
 conductance from muscle microcirculation to
mitochondria is particularly low in CRF patients (10) and after
rHuEPO therapy still remains at 
 
z 
 
70% of that seen in control
subjects. The structural basis of this abnormal O
 
2
 
 transport
conductance is likely microvascular rarification and capillary-
myofiber dissociation provoked by a uremic myopathy (11–
13). As a result of these changes, the ratio of muscle diffusive
to perfusive conductance as defined by Piiper et al. (14–16)
may either not vary (10) or even fall after rHuEPO. Since this
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1.
 
 Abbreviations used in this paper:
 
 CaO
 
2
 
, arterial O
 
2
 
 content; C
 
fv
 
O
 
2
 
,
femoral venous O
 
2
 
 content; DO
 
2
 
, muscle O
 
2
 
 conductance from the
capillary to the mitochondria; [Hb], hemoglobin concentration;
MVC, maximal voluntary contraction; [PCr]/[Pi], ratio of [phospho-
creatine] to [inorganic phosphate]; %[PCr] consumption, phospho-
creatine) consumption during exercise expressed as percent of phos-
phocreatine at rest, measured before each exercise step; pHi,
intracellular pH; O
 
2
 
leg, one-leg O
 
2
 
 delivery; rHuEPO, recombinant
human erythropoietin; O
 
2
 
, whole-body O
 
2
 
 uptake; O
 
2
 
leg, one-leg
O
 
2
 
 uptake.
Q
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ratio determines O
 
2
 
 extraction by muscle, post-rHuEPO O
 
2
 
extraction would not change or may fall (17).
We hypothesize that, in addition to the muscle O
 
2
 
 transport
problem described above, post-rHuEPO muscle bioenergetic
status at a given O
 
2
 
, as reflected by [phosphocreatine] to [in-
organic phosphate] ratio ([PCr]/[Pi]) at rest and during exer-
cise, %[PCr] consumption during exercise, and half-time of
[PCr] recovery after exercise, is below the values observed in
normal sedentary subjects. This defect in muscle cell bioener-
getics may be explained by a cytosolic dysfunction provoked
by uremic myopathy. Since evidence of normal mitochondrial
oxidative capacity in CRF patients has been reported (11,18),
and the companion study showed that O
 
2 
 
peak is O
 
2
 
 supply
dependent in these rHuEPO treated patients, changes in mus-
cle bioenergetics at maximum exercise after rHuEPO therapy
must follow those of maximal O
 
2
 
 flow from muscle capillary to
mitochondria. However, different reports examining muscle
cell bioenergetics in these patients provide conflicting results
(18–22). The primary aim of the present study was the analysis
of the relationships between muscle O
 
2
 
 transport and cellular
bioenergetics, assessed by 
 
31
 
P-nuclear magnetic resonance
spectroscopy (
 
31
 
P-MRS), before and after erythropoietin ther-
apy. Post-rHuEPO data were compared with those obtained in
healthy sedentary subjects. Because we were specifically inter-
ested in the analysis of muscle O
 
2
 
 transport and 
 
31
 
P-MRS data
at maximum O
 
2
 
, the exercise protocol was set to explore ex-
ercise performance above 70% whole-body O
 
2 
 
peak.
 
Methods
 
Patients.
 
Eight anemic subjects (age 27
 
6
 
7.3 [mean
 
6
 
SD] yr), seven
men and one woman, with chronic renal failure undergoing regular
hemodialysis for an average of 12
 
6
 
11 mo, were enrolled in the proto-
V
.
V
.
V
.
V
.
 
col and studied pre- and post-rHuEPO therapy. Anthropometric,
lung function data, adequacy of hemodialysis, and hemoglobin con-
centration [Hb] before and after rHuEPO therapy using standard
dosage (82
 
6
 
12 UI 
 
3
 
 kg
 
2
 
1
 
 
 
3
 
 wk
 
2
 
1
 
) are listed in Table I. Eight addi-
tional healthy sedentary men, selected on the basis of no previous his-
tory of regular or even occasional physical exercise above that re-
quired for the average daily activities, were also studied once using an
identical protocol and were used as a control group (Table I). All
were informed of any risks and discomfort associated with the experi-
ment, and informed consent was obtained in accordance with the
Committee on Investigations Involving Human Subjects at the Hos-
pital Clínic, Universitat de Barcelona. None of these subjects were
the same individuals examined in the accompanying paper (10).
 
Exercise protocol.
 
Exercise tests were performed using an ergo-
meter made of nonmagnetic materials conceived to fit into a standard
whole body magnet. The system, described in detail in reference 24,
allowed flexion and extension of both legs by alternatively pressing
two foot pedals connected to a controlled flow resistance hydraulic
system while the subject lay supine on the ergometer table. A piezo-
electric force transducer (9251A; Kistler Instruments AG, Winter-
thur, Switzerland) placed inside one of the pedals was used to deter-
mine maximum force of contraction (maximal voluntary contraction,
MVC) of the leg and to provide an “on line” control of both strength
and rate of pedalling during the exercise test. The exercise protocol,
performed at 100 cycles 
 
3
 
 min
 
2
 
1
 
, consisted of a maximum of 5 peri-
ods of 2 min exercise at workloads of 20, 25, 30, 35, and 40% of MVC
interspersed by resting periods of 2.5 min. Each subject’s MVC was
calculated as the mean of three measurements. It should be pointed
out that the above mentioned percentages of MVC greatly exceed the
corresponding values of O
 
2
 
 . As reported below, the work load at
20% MVC corresponded to a whole-body O
 
2
 
 value above 70% of
maximum. In each exercise test, the peak workload was defined by
the inability to maintain for 30 s the rate of pedalling due to exhaus-
tion.
 
Study design.
 
In each study, the patient exercised breathing room
air (F
 
I
 
O
 
2
 
 
 
5
 
 0.21) on two different days, less than 1 wk apart, using the
same ergometer and performing the same exercise protocol. On the
V
.
V
.
 
Table I. Anthropometric Data, Lung Function, Adequacy of Dialysis, and Changes in Hemoglobin Concentration
 
Subject Age Height Weight FEV
 
1
 
FEV
 
1
 
/FVC PaO
 
2
 
Kt/V PCR HD Dialyzer [Hb] [Hb]
 
D
 
[Hb]
 
yr cm kg liters %pred % mmHg urea g·k
 
21·day h·w21 pre-rHuEPO post-rHuEPO g·dl21
CRF patients (n 5 8)
VVM 20 173 57 4.3 (98) 85 101 1.0 1.1 12 C 1.4 8.5 11.8 3.3
JCP 41 170 61 3.7 (99) 84 101 1.1 1.0 10.5 CA 1.6 7.8 10.7 2.9
ESG 25 160 54 3.7 (99) 83 112 1.3 1.2 12 C 1.4 7.3 11.2 3.9
JPF 21 163 50 3.9 (99) 84 101 1.1 1.0 10.5 C 1.2 7.6 11.8 4.2
IEC 34 159 59 3.5 (102) 76 99 1.2 1.1 12 CA 1.4 6.6 12.1 5.5
DGR 30 173 62 3.8 (92) 77 97 1.1 1.1 12 C 1.6 8.5 13.3 4.8
ARC 22 178 71 5.4 (95) 85 95 1.3 1.2 12 C 1.8 7.3 11.3 4.0
EMC 24 170 66 3.7 (89) 87 91 1.3 1.2 12 C 1.6 8.6 11.1 2.5
Mean 27 168 60 4.0 (96) 83 100 1.2 1.1 11.6 7.8 11.7 3.9
SD 7 6 7 0.6 4 4 6 0.1 0.1 0.7 1.0 0.8 0.9
Control group (n 5 8)
Mean 26 174 71 4.3 (101) 82 102 14.1
SD 3 5 6 0.7 4 3 1 1.0
Results expressed as mean6SD; CRF patients, eight patients with chronic renal failure; Control group, eight healthy sedentary subjects; FEV1, forced
expiratory volume in the first s in liters, and as percentage of predicted value within parentheses (23); FEV1/FVC, FEV1 to forced vital capacity ratio;
PaO2, PO2 in arterial blood; Kt/V (urea), indicates the decrease of BUN during each dialysis treatment, dimensionless; PCR, protein catabolic rate ex-
pressed in g·k21·d; HD, duration of dialysis in h·wk21 (three times a wk); Dialyzer, type of membrane of the dialyzer and surface expressed in square
meters: C 1.4, Cuprophane 1.4 m2, CA 1.6, Cellulose Acetate 1.6 m2; [Hb] pre-rHuEPO and [Hb] post-rHuEPO, hemoglobin concentration in the pre-
rHuEPO and post-rHuEPO studies expressed in g·dl21, respectively; D[Hb], increase in [Hb] after rHuEPO therapy.
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first day, rest and exercise 31P-MRS were obtained without catheters.
On the second day, the subject followed the identical exercise proto-
col (in time and load) outside the magnet with three catheters in
place to obtain O2 transport data. One of the catheters was placed in
the radial artery of the contralateral side to the arterio-venous fistula
to measure PO2, PCO2, pH, SaO2, lactate, and [Hb] in arterial blood.
In the femoral venous vein of the left leg, a 7-F catheter was advanced
7 cm into the vessel with the tip distally oriented (16), and a 2.5-F
thermistor was advanced 5 cm proximally. Measurements of femoral
venous blood flow by short term steady state thermodilution princi-
ple and measurements of the above variables in arterial and femoral
venous blood were obtained. All patients were strongly encouraged
to maintain the same level of daily physical activity between the pre-
and post-rHuEPO studies despite any improvement in their quality
of life. The time elapsed between pre- and post-rHuEPO studies was
4.261 mo.
31P-MRS measurements. Studies were carried out using a 1.5 T
General Electric Signa Advantage System (General Electric, Milwau-
kee, WI) (160 3 52 cm bore) operating at a frequency of 63.65 and
25.86 MHz for the hydrogen-1 and the phosphorus-31 nucleus, re-
spectively, connected to a Spectroscopy Analysis Workstation SUN
3/470 (Sun Microsystems Inc., Mountain View, CA). Subjects were
placed in the magnet in a supine position, head first, and the elliptical
distributed capacitance surface coil (14.5 3 6.5 cm), pretuned at the
phosphorus resonant frequency, was positioned and fixed over the
vastus medialis muscle of the left leg. Then, the MVC was determined
and the position of the surface coil was checked with spin-echo T1-
weighted images as described in detail in reference 24. Phosphorus-31
Figure 1. Plots of [PCr] and [Pi] (y-axis) over time, expressed in s 
(x-axis). Filled squares correspond to serial measurements carried out 
immediately after an exercise step in a representative patient. Contin-
uous lines represent the monoexponential fitting to measured data 
points used to estimate [PCr] and [Pi] extrapolated at time zero after 
exercise ([PCRt0] and [Pit0], respectively). See Methods for additional 
explanations.
Figure 2. Plots of the 31P-MRS vari-
ables (y-axis) measured during sub-
maximal and peak exercise as a 
function of one-leg O2 uptake ex-
pressed in ml 3 kg21 3 min21 (x-axis). 
[PCr]/[Pi], phosphocreatine to inor-
ganic phosphate ratio at time 0 after 
each workload; %[PCr] consump-
tion, percentage of [PCr] consumed 
during each workload compared to 
the measurements done immediately 
before commencing the exercise at 
each workload; half-time of [PCr] 
recovery during the resting period 
after each work load, expressed in s; 
and, intracellular pH, intracellular 
pH at 8 s after each exercise period. 
In each panel, the three initial work-
loads correspond to measurements 
done at 20, 25, and 30% of MVC, 
which were carried out in all the 
subjects studied. The highest work-
load corresponds to the measure-
ments done at peak exercise. Re-
sults are expressed as mean6SEM.
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spectra were obtained using 1808 pulses as measured at the center of
the coil. A total of 1,024 data points were collected over a spectral
width of 2,500 Hz.
Measurements at rest. Four dummy scans plus 128 transients were
accumulated for each spectrum with a recycling time of 2 s. Before
Fourier transform, a zero filling to 2,048 data points and apodization
by exponential multiplication of 3 Hz were applied to the free induc-
tion decay. Spectra were manually phased and baseline was corrected
using a c-spline function.
Measurements during exercise. After four initial dummy scans,
spectra of 8 transients with a repetition time of 2 s (resolution time of
16 s) were continuously recorded being the first spectrum obtained at
rest before starting the exercise. Before Fourier transform, manual
phase and baseline correction, a zero filling to 2,048 data points and
apodization by exponential multiplication of 5 Hz were applied to the
free induction decay. For all spectra, the area under each resonance
and its chemical shift were obtained after adjusting to pure lorentzian
lines by the Marquardt-Levenberg fitting routine. The spectra col-
lected in the resting period between successive workloads were used
for analysis, but those collected during the 2 min exercise could not
be analyzed because of the movements of the legs. The collection of a
new set of spectra was initiated just after the end of the exercise at
each workload. The phosphocreatine ([PCr]) and the inorganic phos-
phate ([Pi]) concentrations were therefore extrapolated to time 0 af-
ter cessation of exercise at each workload ([PCrt0] and [Pit0], respec-
tively) by fitting the resonance area values to monoexponential
functions with the Enzfitter version 1.03 software package (Elsevier-
Biosoft, Cambridge, UK) (Fig. 1). The [PCrt0] and [Pit0] were used to
calculate the [PCr]/[Pi] ratio, the %[PCr] consumption at each work-
load (%[PCr] consumption), and the individual half-time recovery of
phosphocreatine after each exercise step. The intracellular pH (pHi)
was calculated using the formula: pHi 5 6.75 1 log [(d 2 3.27)/
(5.69 2 d)], where d is the chemical shift distance in ppm between the
Pi and the PCr resonances (25). Both the pHi calculated from the first
spectrum (8 s) after cessation of exercise and that corresponding to
the nadir during the recovery period were analyzed.
O2 transport measurements. Subject preparation, safety precau-
tions, and technical aspects of the measurement of femoral venous
blood gases and blood flow have been described in detail previously
(10, 16, 26). On-line calculations of whole-body O2 uptake ( O2),
CO2 output, minute ventilation, respiratory exchange ratio, heart
rate, and respiratory rate were averaged sequentially over 15 s inter-
vals and then displayed on a screen monitor to observe the progress
of the tests. In each test, measurements were made at rest and during
the second min at each workload. In each instance the following mea-
surements were made: (a) PO2, PCO2, pH (IL model 1302, pH/Blood
gas analyzer and tonometer model 237; Instrumentation Laborato-
ries, Milan, Italy), oxyhemoglobin saturation, hemoglobin concentra-
tion ([Hb]) (IL 482 co-oximeter), and blood lactate concentrations
(YSI 23L blood lactate analyzer; Yellow Springs Instruments, Yellow
Springs, OH) from simultaneous arterial and femoral venous blood
samples; and (b) femoral venous blood flow ( leg) by thermodilu-
tion and arterial pressure. Calculations of the variables have been
previously reported in detail in reference 10.
Data analysis. Results are expressed as mean6SD. After rHuEPO,
changes in leg were compared using an analysis of covariance after
demonstrating existence of a linear relationship between leg and
whole-body O2 (as work rate was increased) with no variations in
the slope from pre- to post-rHuEPO. Comparisons between pre- and
post-rHuEPO studies were done using Student paired t test, and
those between post-rHuEPO and the control group of healthy seden-
tary subjects were carried out using Student unpaired t test. Unless
otherwise stated, comparisons of submaximal exercise were done us-
ing pooled data. Statistical significance was set at P # 0.05.
Results
Anthropometric data, age, lung function, and changes in [Hb]
in the eight CRF patients and the corresponding data from the
eight controls are indicated in Table I. After rHuEPO, [Hb]
increased by 3.960.9 g 3 dl21 (50%), from 7.861.0 to 11.76
0.8 g 3 dl21 (P 5 0.0001).
Effects of rHuEPO therapy on cellular bioenergetics.
Erythropoietin therapy did not affect the phosphocreatine to
inorganic phosphate ratio ([PCr]/[Pi]) either at rest (8.961.2
vs. 8.861.2, pre- and post-rHuEPO, respectively) or, at a given
O2 leg, during exercise (Fig. 2). Likewise, during submaximal
and peak exercise, no significant changes in (a) [PCr] con-
sumption expressed as percentage of the [PCr] measured im-
mediately before each work load (%[PCr] consumption); (b)
intracellular pH (pHi); nor in (c) half-time of [PCr] recovery
V
.
Q˙
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Q˙
V
.
V
.
Figure 3. [PCr]/[Pi] ratio, %[PCr] consumption, and half-time of 
[PCr] recovery, expressed in s, (y-axis) as a function of intracellular 
pH (x-axis). Results are expressed as mean6SEM. See text for addi-
tional explanations.
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Figure 4. Left: Femoral venous 
pH (y-axis) as a function of one-
leg O2 uptake expressed in ml 3 
kg 3 min21 (x-axis). Right: Rela-
tionships between femoral venous 
pH (y-axis) and intracellular pH 
(x-axis) in the three groups. See 
text for additional explanations.
Table II. O2 Transport Variables during Submaximal and Peak Exercise (n 5 8)
Rest 20% MVC 25% MVC 30% MVC
Peak
exercise
P
pre-post
P
post-con
PfvO2 Pre-rHuEPO 32.268.8 22.262.0 22.163.3 20.163.1 20.263.0 0.01 NS
mmHg Post-rHuEPO 44.3613.9 26.266.2 25.564.2 24.764.6 25.965.6
Control 43.8611.9 24.364.2 23.062.7 21.662.1 21.863.1
PfvCO2 Pre-rHuEPO 39.063.3 59.766.6 57.365.3 53.767.3 53.367.2 NS 0.02
mmHg Post-rHuEPO 36.964.0 58.166.8 54.364.3 52.968.0 53.266.9
Control 40.263.4 64.1610.3 63.767.3 62.365.7 62.066.9
pHfv Pre-rHuEPO 7.3960.02 7.2060.05 7.1860.06 7.1760.05 7.1560.05 NS NS
Post-rHuEPO 7.3860.03 7.2160.04 7.1960.04 7.1860.04 7.1660.04
Control 7.4260.04 7.2460.08 7.2060.07 7.1960.06 7.1560.06
CaO2 Pre-rHuEPO 10.760.9 10.860.9 10.860.8 10.960.9 10.960.8 0.001 0.001
m·100ml21 Post-rHuEPO 15.761.0 15.860.9 16.161.1 16.361.1 16.361.2
Control 19.261.4 19.661.5 19.761.9 19.762.0 19.961.8
CfvO2 Pre-rHuEPO 6.960.5 3.760.3 3.360.2 2.960.1 2.960.1 0.001 0.001
m·100ml21 Post-rHuEPO 12.360.9 5.860.4 5.560.3 5.361.0 5.260.4
Control 15.761.0 6.660.7 5.860.5 5.160.4 4.860.4
leg Pre-rHuEPO —— 3.460.6 3.960.8 4.961.5 4.961.5 0.04 NS
liter.min21 Post-rHuEPO —— 3.060.9 3.360.6 3.660.8 3.961.0
Control —— 3.060.4 3.860.6 4.460.5 4.760.8
O2leg Pre-rHuEPO —— 0.3760.09 0.4360.10 0.5260.20 0.5460.19 NS 0.001
liter.min21 Post-rHuEPO —— 0.4760.13 0.5360.08 0.5760.10 0.6360.13
Control —— 0.5960.10 0.7560.15 0.8660.16 0.9460.16
O2 ER Pre-rHuEPO 35614.8 6667.6 6965.3 7364.1 7364.0 0.03 0.05
% Post-rHuEPO 22618.2 6366.9 6566.9 6767.9 6868.2
Control 18614.5 6768.5 7067.1 7465.3 7666.1
O2leg Pre-rHuEPO —— 0.2560.07 0.2960.07 0.4060.16 0.4060.15 NS 0.001
liter.min21 Post-rHuEPO —— 0.2960.07 0.3460.05 0.3860.05 0.4360.09
Control —— 0.3960.07 0.5360.12 0.6460.11 0.7160.13
Results expressed as mean6SD; 20, 25 and 30% MVC, correspond to the submaximal workloads carried out in all the subjects (actual values of each 
of these workloads expressed in watts are indicated in Table III); peak exercise, measurements obtained at exhaustion; Pre-rHuEPO, Post-rHuEPO, 
and Control, results before rHuEPO therapy, post-rHuEPOtherapy, and from the sedentary control subjects respectively; PfvO2, PfvCO2, and pHfv, 
femoral venous PO2, PCO2, and pH, respectively; CaO2, CafvO2, O2 content in arterial and femoral venous blood, respectively; leg, femoral venous 
blood flow; O2leg, one-leg O2 delivery; O2 ER, muscle O2 extraction as a percentage; O2leg, one leg O2 uptake; pre-post, probability of the com-
parisons between pre and post-rHuEPO measurements at peak exercise (paired analysis); post-con, probability of the comparisons between 
post-rHuEPO study and sedentary control subjects at peak exercise (unpaired analysis).
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than in controls (6868.2 and 7666.1%, respectively) (P 5
0.05). The combined effects of O2leg and O2ER on O2 up-
take explain how peak O2leg in CRF patients post-rHuEPO
was 28% lower than that observed in controls (7.261.4 and
10.061.6 ml 3 kg21 3 min21, respectively) (P 5 0.002).
Discussion
Main findings. The present study confirms our previous re-
sults (10) suggesting that the limited increase of maximum O2
uptake ( O2max) in anemic patients with chronic renal failure
(CRF) after increasing the [Hb] up to almost normal levels
with rHuEPO therapy can be essentially explained by: (a) he-
modynamic changes (reduction of leg blood flow) after
rHuEPO; and (b) abnormal muscle O2 conductance from mi-
crocirculation to mitochondria (10). The structural basis for
the reduced muscle O2 conductance in CRF patients is likely to
be a poor muscle microcirculatory network and capillary-myo-
fiber dissociation (11–13) due to uremic myopathy. Two main
findings come from the present investigation.
First, muscle cell bioenergetics as characterized by 31P-MRS
signals reflecting [PCr], [Pi], and derived indices (at rest, dur-
ing exercise, and throughout the recovery period after each ex-
ercise step) did not show significant changes after rHuEPO
therapy. We suggest that in the face of O2 supply limitation of
O2max (10), the lack of significant changes in convective O2
delivery ( O2leg) can explain lack of increase in O2 flow to
mitochondria, and consequently how 31P-MRS data and
O2max both did not change with rHuEPO in the present in-
vestigation. Since O2 supply dependency of O2max in CRF
patients was demonstrated in the companion study (10); lim-
ited mitochondrial oxidative capacity does not appear to ex-
plain the lack of increase in O2max after rHuEPO therapy, if
Q˙
V
.
V
.
V
.
Q˙
V
.
V
.
V
.
after each exercise step, expressed in seconds, were observed
after rHuEPO.
Comparison of 31P-MRS between post-rHuEPO and con-
trols. The [PCr]/[Pi] ratio at rest was significantly higher in
controls than in the post-rHuEPO group (10.961.5 vs.
8.861.2, respectively) (P 5 0.01). As shown in Fig. 2, at a given
O2leg, the energetic status of the muscle cells as reflected by
[PCr]/[Pi], %[PCr] consumption and half-time of [PCr] recov-
ery and the intracellular pH was significantly higher in con-
trols. For example, at a O2leg of z 6.2 ml 3 kg21 3 min21,
the 31P-MRS results were (a) [PCr]/[Pi] ratio, 0.6060.33 vs.
0.2660.13, control and post-rHuEPO group, respectively)
(P 5 0.023); (b) %[PCr] consumption, 68615.5 vs. 8269.7%
(P 5 0.067); (c) half-time of [PCr] recovery, 966.8 vs. 30618.7 s
(P 5 0.013); (d) pHi calculated from the first spectrum (8 s) af-
ter cessation of exercise, 6.7760.15 vs. 6.5560.23 (P 5 0.05);
and (e) pHi corresponding to the nadir during the recovery pe-
riod, 6.6860.16 vs. 6.3760.21), respectively (P 5 0.012). How-
ever, the differences between post-rHuEPO and control group
in [PCr]/[Pi] ratio and %[PCr] consumption during exercise
and in half-time of [PCr] recovery during the interspersed rest-
ing periods disappeared when these variables were expressed
as a function of pHi. Identical results were obtained either us-
ing pHi calculated from the first spectrum (8 s) after cessation
of exercise (Fig. 3) or that corresponding to the nadir during
the recovery period.
Relationships between intracellular pH and femoral venous
pH. No differences in femoral venous pH (pHfv), at a given
O2leg, were observed between pre- and post-rHuEPO stud-
ies. As depicted in Fig. 4 (right), intracellular and femoral
venous pH track each other in all three groups.
Effects of rHuEPO therapy on muscle O2 transport. Arte-
rial O2 content (CaO2) increased by 50% (P , 0.001), parallel
to the rise observed in [Hb] (Table II). However, femoral
venous blood flow ( leg) was consistently lower (220%) at
each workload after rHuEPO (P , 0.04) (Fig. 5). The reduc-
tion in leg largely offset the effect of the increase in CaO2 on
O2 delivery ( O2leg). At peak exercise, O2leg did not
change significantly after rHuEPO, the mean value increasing
by 17%.
We confirmed existence of a low muscle O2 conductance
(DO2) in CRF patients as previously seen (10), but no increase
in DO2 after rHuEPO was found (10.9 6 4.2 and 10.9 6 2.6 ml
3 mmHg21 3 min21, pre- and post-rHuEPO, respectively). As
indicated in Table II, one-leg O2 extraction ratio (O2ER) de-
creased after rHuEPO therapy at each workload. At maxi-
mum exercise, O2ER fell from 7364.0 to 6868.2% (P 5 0.03).
Consequently, the 17% increase in O2leg was counterbal-
anced by the 7% drop in O2ER such that both O2leg (Table
II) and whole-body O2 (Table III) did not change signifi-
cantly (only 18 and 16%, respectively) after rHuEPO therapy.
Comparison of muscle O2 transport at peak exercise be-
tween post-rHuEPO and controls. Muscle O2 transport vari-
ables at peak exercise expressed as percent of the values ob-
tained in the control subjects are shown in Fig. 6
(mean6SEM). Both [Hb] and CaO2 in the CRF patients post-
rHuEPO were z 18% lower than the corresponding values in
the control group, whereas peak leg was similar (6561.1 vs.
6761.2 ml 3 kg21 3 min21, post-rHuEPO and controls respec-
tively). Consequently, O2leg was z 20% lower in CRF pa-
tients post-rHuEPO. As expected from the low muscle O2 con-
ductance in CRF patients, O2ER after rHuEPO was also lower
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Figure 5. Relationships between femoral venous blood flow ( leg), 
expressed in ml 3 kg21 3 min21 (y-axis) and whole-body O2 uptake, 
expressed in ml 3 kg21 3 min21 (x-axis). At any given O2, leg sig-
nificantly decreased after rHuEPO. No differences were detected 
between the post-rHuEPO and controls. Results are expressed as 
mean6SEM.
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we assume that supply dependency was also the case in the
present patient group.
The second major finding was that the 31P-MRS results
(Fig. 2) depict a lower muscle cell bioenergetic status and a
lower intracellular pH (pHi), at a given O2leg, in CRF pa-V
.
tients post-rHuEPO compared to controls. The longer half-
time of [PCr] recovery in CRF patients would suggest reduced
mitochondrial function, but because of the complexity of the
processes regulating oxidative phosphorylation in the mamma-
lian cell (26), the identification of the precise mechanism(s) re-
sponsible for the observed differences between CRF patients
and controls is beyond the scope of the present study. How-
ever, it should be pointed out that the differences in [PCr]
breakdown and in half-time of [PCr] recovery between CRF
patients post-rHuEPO and control disappeared when these
variables ([PCr]/[Pi] ratio, %[PCr] consumption and half-time
[PCr] recovery) are expressed as a function of pHi (Fig. 3). In-
crease in half-time of [PCr] recovery related with low pHi val-
ues, but not due to changes in muscle O2 supply, has been re-
ported by McCully et al. (28). Low pHi values increase the
half-time of [PCr] recovery as a result of the effect of [H1] on
the creatine kinase reaction such that PCr levels no longer
strictly depend on changes in ADP concentration. Low pHi
can also inhibit adenosinetriphosphatase rates and lower oxi-
dative capacity (29). The behavior of these energetic indices as
a function of pHi suggests that the 31P-MRS abnormalities may
be primarily due to [H1]-related cytosolic effects on the regu-
lation of the processes involved in [PCr] breakdown and resyn-
thesis rather than to a primary disturbance of the mitochon-
drial oxidative capacity (30, 31). The marked differences in
pHi between patients and controls, at a given O2leg, may be
in larger part explained by different lactate levels (Table III),
although without intracellular lactate concentrations this is
somewhat speculative. The slightly lower [Hb] (Table I) ob-
served in post-rHuEPO patients compared with controls does
not perturb the interpretation of the differences in cellular
bioenergetics.
V
.
Figure 6. Results of muscle O2 transport variables expressed as per-
cent of the values obtained in the sedentary control subjects. leg, 
O2leg, and O2leg have been corrected by body weight. Values are 
expressed as mean6SEM. *P , 0.05 between pre- and post-rHuEPO 
(Student’s paired t-test); ‡P , 0.05 between post-rHuEPO and con-
trols (Student’s unpaired t-test).
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Table III. Whole-body Variables during Submaximal and Peak Exercise (n 5 8)
Rest 20% MVC 25% MVC 30% MVC
Peak
exercise
P
pre-post
P
post-con
Watts Pre-rHuEPO 0 3367 42610 53612 57616 NS NS
Post-rHuEPO 0 3367 42610 53612 55617
Control 0 3666 47611 58616 65617
O2 Pre-rHuEPO 0.2560.05 1.2660.25 1.4460.34 1.6460.42 1.6760.54 NS NS
liters·min21 Post-rHuEPO 0.2860.07 1.3960.40 1.5260.45 1.6560.33 1.7760.48
Control 0.2760.06 1.4060.36 1.7060.23 1.9060.22 2.0360.30
O2 Pre-rHuEPO 4.161.0 20.964.2 24.066.0 26.466.2 27.668.0 NS NS
ml·min21kg21 Post-rHuEPO 4.861.2 23.566.7 25.767.7 27.965.7 29.866.9
Control 3.860.7 19.765.0 24.063.7 26.463.5 28.764.6
HR Pre-rHuEPO 84614 136616 151620 163613 164610 NS NS
min21 Post-rHuEPO 81613 134620 152622 163611 168610
Control 76612 129624 155623 164620 17168
[Lact]a Pre-rHuEPO 0.660.2 3.060.7 5.761.5 7.862.1 8.662.7 0.01 0.04
mM Post-rHuEPO 0.560.2 2.661.4 4.261.9 5.762.3 6.061.9
Control 0.660.2 2.760.6 5.261.7 6.761.8 7.861.1
Results expressed as mean6SD; 20, 25 and 30% MVC, correspond to the submaximal workloads carried out in all the subjects (actual values of each 
of these workloads expressed in watts are indicated in this table); peak exercise, measurements obtained at exhaustion; Pre-rHuEPO, Post-rHuEPO, 
and Control, results before rHuEPO therapy, post-rHuEPO therapy, and from the sedentary control subjects respectively; Watts, workload at each 
exercise step expressed in watts; O2, O2 uptake; HR, heart rate; [Lact]a, lactage concentration in arterial blood expressed in mM; pre-post, 
probability of the comparisons between pre and post-rHuEPO measurements at peak exercise (paired analysis); post-con, probability of the 
comparisons between post-rHuEPO study and sedentary control subjects at peak exercise (unpaired analysis).
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Structural and histochemical findings in skeletal muscle bi-
opsies obtained in CRF patents (11–13) indicate poor capillary
network and capillary-myofiber dissociation as the foremost
characteristic findings, but also myopathic changes that could
decrease oxygen-dependent metabolism. Abnormal oxidative
capacity is claimed to exist in CRF patients by some authors
(19). Diesel et al. (13) also argued for a reduced muscle oxida-
tive capacity in CRF patients but these authors used an inade-
quate control group consisting of trained athletes rather than
sedentary subjects. In contrast, Moore et al. (18) suggest pre-
served intrinsic oxidative mitochondrial capacity in dialysis pa-
tients as compared to transplant recipients and healthy sub-
jects, based on their similar post-exercise recovery of [PCr]/
[Pi] ratio and pHi to baseline energy status. The present study
provides two new insights compared to the work done by
Moore et al. (18). First, we examine the effects of a marked in-
crease in [Hb] after rHuEPO therapy (by 50%) on muscle
bioenergetics. Second, in the present study interpretation of
energetic status of the cell (both in the comparison between
pre- and post-rHuEPO therapy and in the analysis of the dif-
ferences between CRF patients post-rHuEPO and healthy
sedentary controls) was done, for the first time, using actual
muscle O2 transport and O2 uptake data obtained while the
subject was performing identical exercise protocol and using
the same ergometer. Hence, unnecessary assumptions and un-
certainties such as the nature of static and dynamic hand-grip
exercise (18) can be avoided.
Differences in O2 transport response to rHuEPO between
the present study and reference 10. Despite the marked increase
in [Hb] in both investigations (50 and 69%, present study and
reference 10, respectively), the weak O2 transport response af-
ter rHuEPO in the present protocol was indeed more evident.
The fall in leg after rHuEPO was slightly greater than that
seen in reference 10, and at variance with the previous study,
muscle oxygen extraction ratio (O2ER) significantly decreased
after rHuEPO. These two phenomena can account for the lack
of change in one-leg O2 uptake at peak exercise after
rHuEPO. A similar lack of response to the rHuEPO therapy
was also found in whole-body O2 uptake at peak exercise
which, as indicated in Methods, is a fully independent mea-
surement from one-leg O2 ( O2leg). Since all measurements
were done while subjects were breathing room air only, DO2 in
this study is analyzed subject to the assumption of O2 supply
dependency which was demonstrated in reference 10. The
technical requirements to estimate muscle O2 conductance
have been analyzed in detail elsewhere (10, 16, 32–35). How-
ever, it is of note that post-rHuEPO DO2 in these patients
(10.961.6 ml 3 mmHg21 3 min21) was z 60% of that ob-
tained in controls (18.263.5 ml 3 mmHg21 3 min21). As sug-
gested by Piiper et al. (14) and shown elsewhere (10, 16), the
observed reduction of the O2ER after rHuEPO from 7364.0
to 6868.2% (P , 0.03) necessarily requires a decrease in diffu-
sional to perfusional conductance ratio (DO2/b 3 leg) after
rHuEPO. The term b corresponds to the slope of the O2 disso-
ciation curve and is the ratio of the arterial to femoral venous
O2 content difference and the arterial to femoral venous PO2
difference [b 5 (CaO2 2 CfvO2)/(PaO2 2 PfvO2)].
The above described differences in muscle O2 transport be-
tween these two investigations (present study and 10), as well
as the lack of change in DO2 after rHuEPO in the present
study, can be ascribed to the combined effects of two factors:
(a) the smaller increase in [Hb] after rHuEPO in this study
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compared to reference 10 (50 vs. 69%, respectively); and (b)
the larger reduction in peak leg after rHuEPO in the present
investigation (by 220%, from 82 to 65 ml 3 kg21 3 min21)
compared to that observed in reference 10 (by 213%, from 84
to 73 ml 3 kg21 3 min21). The two groups of CRF patients
showed a similar exercise performance (relationships between
O2 and work rate and peak O2), evaluated using a regular
cycloergometer (post-rHuEPO whole-body O2max, 30.666.6
and 33.164.7 ml 3 kg21 3 min21, present study and reference
10, respectively). The present study and reference 10 were per-
formed at the same time using identical inclusion criteria.
31P-MRS data at rest. Differences of resting [PCr]/[Pi] ra-
tios have been reported among normal sedentary subjects,
sprinters, and long-distance runners (36), likely reflecting dif-
ferent bioenergetic status associated with differences in muscle
fiber-type composition. However, a low [PCr]/[Pi] ratio at rest
is a characteristic feature of several different metabolic myop-
athies (37, 38). In the present study, pre-rHuEPO results were
below (P 5 0.01) those seen in the control group with no sig-
nificant changes after rHuEPO, indicating a lower muscle en-
ergetic status in CRF patients (pre- and post-rHuEPO). We
suggest this is probably due to uremic myopathy, rather than
related to an abnormal O2 supply to mitochondria which, at
rest, can be assumed largely above cellular O2 demand. Lower
[PCr]/[Pi] ratios in CRF patients compared to their controls (P ,
0.01) have also been reported by Táborsky et al. (19). In con-
trast, Moore et al. (18) and Durozard et al. (21) have described
a normal resting muscle bioenergetic status in CRF patients. It
is of note that Park et al. (20) reported a low [PCr]/[Pi] ratio in
CRF patients pre-rHuEPO followed by an increase after
rHuEPO therapy, from 6.161.1 to 8.762.1, which has not been
confirmed in the present study. Discrepancies among authors
can likely be ascribed to technical factors and differences in
the muscle groups explored.
Exercise protocol. We focused the study on the analysis of
the relationships between muscle O2 transport and cellular
bioenergetics at maximum exercise. Consequently, the exer-
cise protocol was specifically designed to examine the perfor-
mance above 70% whole-body O2peak. Recall that the per-
centages of maximal voluntary contraction (%MVC), reported
in Tables II and III, greatly exceed the corresponding percent-
ages of whole-body O2peak. The marked changes in pHi
throughout exercise observed in all the groups (Fig. 2, bottom
right) might constrain the analysis of changes in [PCr]/[Pi] ra-
tio, %[PCr] consumption, and half-time of [PCr] recovery as
markers of mitochondrial oxidative capacity. The latter is of-
ten explored using submaximal exercise protocols that pro-
voke negligible changes in pHi. To cope with this potential
limitation in the interpretation of the results, the 31P-MRS data
were also expressed as a function of pHi, as indicated in Fig. 3
and discussed below. An interesting finding of the present
study is the strong correlation between femoral venous pH and
pHi in the three groups (Fig. 4). Moreover, to reach high inten-
sity levels of exercise, the protocol was set at 100 cycles 3
min21 which, in turn, precluded the analysis of the spectra dur-
ing the leg movements. As indicated in Methods, the PCr and
Pi data were extrapolated to time 0 after each work load, and
the derived variables ([PCr]/[Pi] ratio, %[PCr] consumption
and half-time of [PCr] recovery) were obtained from [PCrt0]
and [Pit0]. Both the correlation of the measured data to a mono-
exponential function, as shown in Fig. 1, and indeed the consis-
tency of the 31P-MRS data during exercise indicate that the
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characteristics of the protocol allowed for the analysis of the
relationships between O2 supply and cellular bioenergetics in
the setting.
Effects of rHuEPO on muscle cell bioenergetics during ex-
ercise. The analysis of submaximal and peak exercise data
(Fig. 2) clearly shows that [PCr]/[Pi] ratio and %[PCr] con-
sumption, at a given VO2leg, did not change after rHuEPO.
Intracellular pH and half-time of [PCr] recovery also did not
show significant changes. The lack of effects of rHuEPO on
the 31P-MRS data, at a given VO2leg, suggests that either: (a)
biochemical pathways (i.e., mitochondrial oxidative capacity)
not related to O2 supply to the cell may determine the bioener-
getic status of the muscle cells in these patients; or (b) that
rHuEPO, despite the marked increase in [Hb] (by 50%), did
not effectively increase maximal O2 flow to the myocytes. The
latter is the most likely explanation for the 31P-MRS data de-
picted in Fig. 2 as described above. The lack of changes in mus-
cle O2 transport after rHuEPO are consistent with this notion.
Moreover, since O2 supply dependency of maximum O2 up-
take in CRF patients was demonstrated in the companion
study (10), a reduced oxidative capacity appears unlikely to ex-
plain the lack of changes in muscle cell bioenergetics after
rHuEPO. Thompson et al. (18) have reported 31P-MRS data
measured in three CRF patients studied pre- and post-
rHuEPO therapy. These authors suggest that both impaired
muscle O2 transport and limited mitochondrial oxidative ca-
pacity play a role limiting maximum exercise performance in
these patients. However, the lack of a parallel assessment of
muscle O2 transport in their study limits the interpretation of
their results.
In summary, the present study confirms that: (a) reduction
in muscle blood flow and (b) abnormal intramuscular O2 trans-
port due to functional and structural derangement of muscle
microcirculation provoked by uremic myopathy can explain
the poor peak O2leg response after rHuEPO therapy. The
lower pHi, at a given O2leg, seen in CRF patients compared
to controls, may be also partially explained by the low capillar-
ity associated to uremic myopathy. This low pHi seems to ac-
count for the lower [PCr]/[Pi] ratio and the longer half-time of
{PCr] recovery, at a given O2leg, seen in these patients. How-
ever, derangement of the cytosolic regulation of oxidative
phosphorylation directly provoked by uremic myopathy can
not be ruled out.
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